KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Beginning Cash Balance fell 4.30% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 47.47%. This contributed to the annual value of $3.2 billion for FY2024, which is 13.87% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Beginning Cash Balance stood at $2.2 billion for Q3 2025, which was up 27.34% from $1.7 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Beginning Cash Balance ranged from a high of $3.3 billion in Q4 2024 and a low of $1.7 billion during Q2 2025.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Beginning Cash Balance value was $2.7 billion (recorded in 2023), while the average stood at $2.6 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Beginning Cash Balance soared by 47.53% in 2024 and then tumbled by 43.26% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Beginning Cash Balance (Quarterly) stood at $2.0 billion in 2021, then climbed by 10.59% to $2.2 billion in 2022, then increased by 1.08% to $2.2 billion in 2023, then skyrocketed by 47.53% to $3.3 billion in 2024, then fell by 4.30% to $2.2 billion in 2025.
  • Its Beginning Cash Balance stands at $2.2 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $3.3 billion for Q1 2025.